Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial - Marston, Nicholas A.; Kamanu, Frederick K.; Nordio, Francesco; Gurmu, Yared; Roselli, Carolina; Sever, Peter S.; Pedersen, Terje R.; Keech, Anthony C.; Wang, Huei; Lira Pineda, Armando; Giugliano, Robert P.; Lubitz, Steven A.; et al. (Circulation (New York, N.Y.), 2020)
Keywords: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - therapeutic use; Anticholesteremic Agents - therapeutic use; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - etiology; Cholesterol, LDL - blood; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; PCSK9 Inhibitors; Placebo Effect; Polymorphism, Single Nucleotide; Proportional Hazards Models; Proprotein Convertase 9 - genetics; Proprotein Convertase 9 - metabolism; Risk Factors; cardiovascular disease; risk factors; genetics; PCSK9 protein, human; evolocumab